I N T R O D U C T I O N
Chronic kidney disease (CKD) is a worldwide public health problem resulting in poor clinical outcomes [1] . The number of patients diagnosed with CKD is increasing rapidly and the number of deaths due to CKD almost doubled between 1990 and 2010 [2] . Advanced CKD often leads to end-stage renal disease (ESRD), which is characterized by excessive mortality rates. The mortality rate of ESRD patients on dialysis is nearly 20 times higher than that of the general European population [3] . Survival varies substantially among patients, depending for example, on age at the start of dialysis, primary kidney disease, comorbidity and residual renal function at start of dialysis [4] .
Monitoring renal function in patients with CKD is of paramount importance to estimate prognosis, optimize therapy and ultimately help decide when to start renal replacement therapy (RRT). Many studies in the general population have shown that a single estimated glomerular filtration rate (eGFR) on the basis of serum creatinine, gender and age of <60 mL/min/1.73 m 2 is an independent predictor of mortality [5] . In addition, studies in the general population or in patients with CKD stage 3 showed that especially the rate of decline in eGFR is associated with increased mortality [6] [7] [8] [9] [10] [11] . In line with these results, it has been proposed to incorporate this rate of decline in the otherwise static definition of CKD stages, as it gives more information on the patient's disease state than a single eGFR determination [6, 9, 10, 12] .
In patients with advanced CKD progressing towards dialysis, the effect of renal function on mortality is less clear. The eGFR just before or at start of dialysis has been shown to be not, or even inversely related to, mortality on dialysis [4, 13, 14] . The only randomized controlled trial on the effect of starting dialysis at a low or higher eGFR (calculated with the Cockroft-Gault formula) showed no effect on mortality [15] . The effect of renal function decline in the months prior to dialysis on death has hardly been studied. After correction for confounding, Haapio et al. found no association between eGFR decline calculated with the Modification of Diet in Renal Disease (MDRD) formula in the year prior to starting RRT, and mortality on dialysis [16] . O'Hare et al. found that patients with a steeper eGFR trajectory (by MDRD) had a higher risk of death in the first year after dialysis, however these were mainly patients with acute kidney injury (AKI) [17] .
A major limitation of most of the above-mentioned studies is the use of an estimated glomerular filtration rate [4, 6, [8] [9] [10] [11] [13] [14] [15] [16] . This eGFR has been shown to overestimate the glomerular filtration in patients with ESRD and is inversely associated with muscle mass [18] . Therefore, it may not be suitable for interpreting GFR slopes as marker of kidney disease progression in ESRD patients, and may even lead to discrepancies of renal function measures in their relationship to mortality [18] [19] [20] . As decline in renal function may be better reflected by the mean of the measured creatinine and urea clearance based on 24-h urine collections (mGFR, by C Cr-U ) [21, 22] , we hypothesize that in patients with low kidney function, a fast mGFR decline is a risk factor for mortality on dialysis, in contrast to a fast eGFR decline.
The aim of the present study was to explore the effect of fast versus slow mGFR pre-dialysis decline on mortality during dialysis, and to compare the results with the possible effect of fast versus slow eGFR pre-dialysis decline on mortality.
M A T E R I A L S A N D M E T H O D S

Study design
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD-II) is a prospective multicentre cohort study in which ESRD patients with CKD, who started dialysis treatment in 38 dialysis centres in the Netherlands between January 1997 and January 2007, were included. The study was approved by all local medical ethics committees. Data on mGFR (by C Cr-U ) and eGFR (by MDRD) during the pre-dialysis period, collected from medical records, were added retrospectively to this prospective cohort for patients included before 2003. Before participating in NECOSAD and adopting its protocols, many centres already collected 24-h urine samples in pre-dialysis patients. However, some centres measured GFR at irregular intervals and used only creatinine clearance instead of the combined creatinine and urea clearance to do so. Available lab and 24-h urine assessments of creatinine and urea were retrospectively collected from patient records in the pre-dialysis period. A maximum of eight measurements during a 2-year period before dialysis initiation were added to the NECOSAD database. The plasma creatinine was measured per dialysis centre using the local methods, which was predominately the Jaffe method. A pilot study comparing these measurements with more precise enzyme-mediated methods found that the differences were negligible. Follow-up data on death were available until February 2015.
Patient inclusion
Patients were eligible for inclusion in NECOSAD if they were at least 18 years of age, started RRT for the first time and had provided written informed consent. For the present study, patients with at least two mGFR and eGFR measurements in the pre-dialysis period up to the start of dialysis were included. From this group we excluded patients in whom the time between the first and last pre-dialysis mGFR or eGFR value was shorter than 30 days. This was done because a shorter time frame gives an unreliable estimation of the decline. See Figure 1 for a flowchart of patient inclusion.
GFR slopes and exposure categorization
The mean of endogenous creatinine and urea clearance in 24-h urine collection, corrected for the body surface area, was used to calculate the measured GFR. We refer to this measure for GFR as mGFR (by C Cr-U ) with mL/min/1.73 m 2 as the unit of measurement. The eGFR in mL/min/1.73 m 2 was calculated using the '186' 4-item MDRD formula; this is referred to by eGFR or eGFR (by MDRD) in the current study. See Appendix 1 for the mGFR and eGFR formulas used. Individual annual mGFR and eGFR declines were estimated using linear regression. This means we assume a linear decline (as opposed to exponential), which is a safe assumption considering the relatively short follow-up period (194 days on average) and that patients suffered from CKD. Patients were divided into two categories based on the rate of decline in renal function: those with fast decline (>4 mL/min/1.73 m 2 /year) and those with slow decline ( 4 mL/min/1.73 m 2 /year). The cut-off value of 4 mL/ min/1.73 m 2 GFR decline per year is based on the KDOQI guidelines and on multiple studies that have shown that a decline in GFR that exceeds 4 mL/min/1.73 m 2 /year can be considered fast and is associated with serious complications [12, 23, 24] .
Statistical analysis
Data are presented as mean values with standard deviations for continuous variables and as percentages for categorical variables, unless stated otherwise. For all patients included in the study, the start of dialysis treatment was regarded as the baseline. Baseline differences between the fast and slow decline group were assessed using an unpaired t-test for continuous variables and a chi-squared test for categorical variables.
Survival by mGFR and eGFR decline was calculated by using the Kaplan-Meier method, in which patients were censored either on 1 February 2015 or on the date of kidney transplantation, recovery of renal function, withdrawal from the study or a
transfer to a dialysis centre that did not participate in the study. Cox proportional hazards regression was used to calculate hazard ratios (HRs) separately for mortality based on mGFR decline rate and for mortality based on eGFR decline rate. Correction for confounding factors was performed in two steps. In the first model we only corrected for the basic confounders gender and age. In the second model we added the following confounders: primary kidney disease, cardiovascular disease, diabetes mellitus (as comorbidity), cancer, ethnicity, smoking and mean level of mGFR or eGFR, respectively. The variable primary kidney disease includes the following four categories: diabetes mellitus, glomerulonephritis, renal vascular disease and other diseases. In case of missing confounder data we applied available case analysis. We did not correct for variables that were potentially in the causal pathway between pre-dialysis kidney function decline and mortality.
To validate the robustness of our results we performed several sensitivity analyses for mGFR and eGFR decline. First, we varied the minimal time interval of 30 days between the first and last GFR value and analysed the patients separately with a minimum of three GFR measurements. Secondly, we varied the cut-off point for the distinction between fast and slow decline and analysed the decline as a continuous exposure as well as a proportional decline. Sensitivity analyses were also performed using the CKD-EPI eGFR formula and the 175 MDRD formula. Subgroup analyses were performed for haemodialysis (HD) and peritoneal dialysis (PD), as well as for diabetics and non-diabetics. We also performed a best-case scenario analysis in which we assumed that patients who received a transplant or recovered renal function remained alive until the end of follow-up. An analysis excluding these transplanted and recovered patients was performed as well. We also performed a sensitivity analysis to validate that eGFR and mGFR are independent factors and lastly analyses adding serum albumin and subjective global assessment (SGA) as confounders were performed. All statistical analyses were performed with SPSS version 20.
R E S U L T S
Characteristics of the study population
General pre-dialysis data were retrieved for 1130 out of 1756 patients included before 2003. For 376 of these patients both creatinine and urea clearance based on 24-h urine samples were available to calculate the mGFR (by C Cr-U ). Of these 376 patients a total of 197 had at least two mGFR and eGFR values recorded during the pre-dialysis phase and had a minimum of 30 days between the first and the last pre-dialysis measurement (Figure 1 ). The median time between the first and last recorded 
pre-dialysis GFR value was 204 days with an interquartile range (IQR) of 92-312 days. Baseline characteristics at the start of dialysis for fast and slow mGFR decline are shown in Table 1 . Missing data were rare, at an average of 0.5% and a maximum of 2.4%. Among the 197 patients, 121 (61%) had a mGFR decline rate during pre-dialysis that exceeded 4 mL/min/1.73 m 2 ; they were considered fast decliners. Patients with fast decline were slightly younger at baseline and more likely to be male. Risk factors more common in patients with a fast decline included smoking, cardiovascular disease and hypertension. The group of 76 (39%) patients with slow mGFR decline had a higher frequency of cancer and were more likely to be treated with one of the following medications: angiotensin-converting enzyme inhibitors, b-blockers and/or diuretics.
The decline rate was also assessed based on eGFR measurements. Among the 197 patients, 111 (56%) had a fast eGFR decline rate during pre-dialysis and 86 (44%) had a slow eGFR decline rate. Baseline characteristics on the fast and slow decline groups based on eGFR can be found in Table 2 .
Survival associated with GFR decline
Of all included patients, 78 (39.6%) died during the 12 years of follow-up. In the slow mGFR decline group 24 patients (31.6%) died, compared with 54 patients in the fast decline group (44.6%). The median (IQR) length of time on dialysis was 919 (443-1576) days. In the crude Cox analysis the fast mGFR decline group had a significantly higher risk of death compared with the slow mGFR decline group, with an HR of 1.84 [95% confidence interval (CI): 1.13-2.98], as shown in Table 4 and Figure 4 . When adjusted for age and gender in model 1, this association became stronger with an HR of 2.14 (95% CI: 1.31-3.48) for death in patients in the fast decline group, compared with slow decline. In model 2 a strong and significant association between mortality and fast mGFR decline was still present, with an HR of 1.94 (95% CI: 1.11-3.36). Decline rates are presented as median (IQR), values at dialysis initiation as mean (standard deviation).
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We compared the results of fast and slow decliners based on mGFR values with the results of fast and slow decliners based on eGFR values. In the slow eGFR decline group 31 patients (36.0%) died, compared with 47 patients in the fast decline group (42.3%). In the crude Cox analysis the fast eGFR decline group did not have a higher risk of death compared with the slow eGFR decline group, with an HR of 1.20 (95% CI: 0.75-1.89), as shown in Table 4 and Figure 5 . When adjusted for age and gender the HR remained almost the same with an HR of 1.06 (95% CI: 0.66-1.70). In model 2 the HR of fast eGFR decline was 1.14 (95% CI: 0.67-1.94) compared with slow decline.
To investigate the robustness of these results, multiple sensitivity analyses were performed for the mGFR decline as well as for the eGFR decline. Repeating the analyses with a minimum required interval of 15 days and 45 days between the first and last GFR value did not change the results. The results also did not change substantially when only analysing the patients who had a minimum of three pre-dialysis GFR measurements available. The classification between slow and fast decline was tested by additional analyses in which the study population was divided into two groups based on the median GFR decline rate, a decline of >5 mL/min/1.73 m 2 /year (as recommended by the KDIGO guidelines [25] ) and in tertiles and quartiles of GFR decline. All classifications showed the same pattern of association, and thus confirmed stability of results, though the HRs are smaller when using the KDIGO definition of fast versus slow decline. Using the continuous decline as an exposure as well as a relative decline confirmed previous findings. Using the CKD-EPI or 175 MDRD formula practically did not change the HRs. Subgroup analyses for HD and PD as well as for diabetics and non-diabetics showed similar results. The best-case scenario and exclusion of transplanted and recovered patients analyses show that censoring these patients is acceptable. Adding mGFR decline as a confounder to the eGFR Cox models did not alter our conclusions. Finally, adding serum albumin and SGA as confounders increased the strength of the association, though these results should be interpreted carefully as albumin and SGA might be in the causal pathway. Results of all sensitivity analyses can be found in the Supplementary data, Tables S1-S20.
D I S C U S S I O N
According to the present study a fast mGFR decline (by C Cr-U ) in the pre-dialysis phase is associated with an almost twice as high a level of mortality on dialysis, compared with a slow mGFR decline. This association remained strong when adjusting for multiple confounders and was validated with multiple sensitivity analyses. In contrast, there was no association found between a fast eGFR decline (by MDRD) in the pre-dialysis phase and mortality on dialysis. This study demonstrates the importance of mGFR decline and gives incentive for repeated mGFR measurements as opposed to only assessing eGFR in patients who are in the final phases before dialysis initiation. The study has a number of limitations. We studied retrospective pre-dialysis data that physicians had requested for their patients during regular outpatient visits. As a consequence, mGFR values were only available for a limited number of patients; this might have resulted in selection bias. Although in Dutch pre-dialysis care it has been standard practice to measure the mGFR based on 24-h urine samples periodically, before dialysis centres were included in NECOSAD, there was no consensus on the optimal way to calculate this mGFR (by creatinine clearance, urea clearance or a combined creatinine and urea clearance). Yet, there were already a number of dialysis centres and nephrologists who measured renal function using the mGFR based on creatinine and urea clearance in 24-h urine collections. The patients in whom this combined mGFR was measured could theoretically be different from the average dialysis patient. However, based on the patient characteristics of the included patients and the study design, we deem this unlikely. Another way in which selection bias might have occurred is that a specific group of patients did not collect their urine successfully, since the collection of urine for 24 h can be very challenging. Of the patients in whom the combined mGFR was measured, not all patients (n ¼ 108) met the minimum of two or more mGFR pre-dialysis values. When a 24-h urine collection was considered inaccurate it was not recorded by the attending nurse or physician. In discussion with nephrologists, we hypothesized that sicker patients might not feel up to urine collection, however one could also imagine that healthy active patients would find urine collection more troublesome and would not have time for it. We thus assume that the amount of unsuccessful urine collections is practically randomly distributed over the study population and would only have resulted in dilution of the effect. In conclusion, we cannot exclude the possibility of selection bias having occurred. However, we do not think this bias could have influenced our results a great deal, as we measured both mGFR and eGFR in the same patients. If this possible selection bias influenced our results we would have expected to find a similar association between eGFR decline and mortality, which was not the case. Nonetheless, this study should be replicated on prospective data to verify the results.
The upside to the retrospective data collection is that our pre-dialysis data are an excellent representation of everyday clinical practice, thus making our results more convincing and applicable for nephrologists.
Another limitation might be that it is impossible to be certain that all patients with AKI were excluded from NECOSAD. However, repeated pre-dialysis measurements with a minimum of 30 days are unlikely to take place in AKI patients and patients with apparent AKI were excluded from the study by their nephrologists.
Lastly, one can never be completely certain that there is no residual confounding; renal function decline could be a marker for other patient characteristics that cause mortality. However, adjusting for many patient characteristics that might give confounding had no effect on our results. Since patients initiating dialysis were the source population, we do not have any data on patients that might not have reached dialysis. If one wanted to intervene on this decline, more studies with a prospective set-up would be necessary to verify our results. We assume that predialysis dropout is limited from experience in the PREPARE study, which is a similar population to NECOSAD. In the PREPARE study pre-dialysis patients were prospectively included and very few patients died, received transplants or recovered renal function before the initiation of dialysis [26] .
The current study has a number of strengths. First of all, few studies are available that specifically focus on the course of GFR leading up to the start of dialysis. Instead, many studies have only reported on single determinations of renal function. There are great benefits to studying a period instead of a single moment in time, as decline in renal function is far more meaningful and robust than a single measurement. Also, the use of linear regression to analyse the decline makes for an easy-toreplicate and intuitive method, though it is not applicable to patients with AKI [17, 27] . Finally, one of the major strengths of our study is that we have measured the glomerular filtration rate based on 24-h urine samples, as well as estimated GFR. This is especially important since the study was performed in patients with CKD stages 4 and 5, right before dialysis initiation usually takes place.
In the current patient population with low GFR values ranging from approximately 30 to 10 mL/min/1.73 m 2 the serum creatinine values differ greatly from patients with a higher GFR, mainly due to muscle wasting. As the eGFR formulas do not incorporate the individual patients' body weight, these values do not reflect the underlying actual mGFR in an optimal fashion. Although 24-h urine collections may contain collection errors, the error associated with alterations in body composition and thus creatinine production seems to outweigh this limitation at these low levels of renal function. This is in line with previous literature that has shown the validity of serum creatinine-based formulas for estimating renal function to be limited in CKD stage 4 and 5 and in older patients with comorbidity [18, 28] . A study by Beddhu et al. showed that paradoxically, a higher eGFR (by MDRD) at the start of dialysis was associated with an increased risk of death although a higher measured clearance of creatinine had no association with mortality [29] . In contrast, studies performed in patients with higher GFR or larger ranges of kidney function show that a creatinine-based eGFR could be equivalent or superior as a predictor of certain adverse outcomes compared with mGFR based on exogenous markers [30] [31] [32] [33] [34] . A recent publication by Hsu et al. showed that an abrupt decline of eGFR in patients with mild to moderate CKD was associated with a higher risk of death after initiating HD therapy [35] . In general CKD patients, a U-shaped mortality curve has been found, where both patients with a fast decline of eGFR and patients with an increase in eGFR had an increased mortality risk [6, 10] . It was hypothesized that this paradoxical finding was due to muscle wasting. Both studies were performed in exclusively CKD patients and did not examine mortality on dialysis.
To our knowledge we are the first to study the effect of predialysis decline in renal function on mortality on dialysis using mGFR calculated from 24-h urine samples. Our results regarding eGFR are in line with the results of Haapio et al., who studied eGFR decline rate and survival on RRT 1 year prior to RRT in 319 patients [16] . Dividing the patient group into tertiles according to eGFR slope, they found that the most rapid decline group (>8.5 mL/min/1.73 2 /year) had a higher mortality on RRT (HR: 1.7, 95% CI: 1.2-2.4) but this association was no longer significant when adjusted for confounders. Since mortality on dialysis is extremely high it is important to find risk factors specific to these patients, as done in the current study.
The mechanisms underlying the association between the rate of renal function decline and mortality remain unclear. Blood pressure might be an underlying mechanism since hypertension is a well-established risk factor for progressive loss of renal function in ESRD [36] . However, the link between hypertension and survival in chronic HD patients is less clear [36, 37] . Another possible mechanism could be the amount of residual kidney function (RKF) that a patient retains throughout dialysis. One could imagine that patients with a rapid loss of mGFR on predialysis have a higher loss of RKF after dialysis initiation. This would support close monitoring of RKF in the peri-dialytic period. Previous studies have shown that retaining residual renal function, as compared with the full loss of GFR, is associated with better survival and quality of life in dialysis patients [38] [39] [40] . More research is warranted to understand the relation between pre-dialysis GFR loss and RKF on dialysis. There are many risk factors for mortality on dialysis that a nephrologist keeps in mind when treating pre-dialysis patients. This study underlines the importance of taking mGFR decline into account as a risk factor to help predict the prognosis of patients, decide how often a patient should be monitored and decide when the ideal time would be to start dialysis for each individual patient. Although the collection of 24-h urine requires more effort than a single blood sample, we found that mGFR decline in patients with low kidney function is an independent risk factor for mortality and thus should play a larger part in patient-centred care.
In conclusion, our study shows that fast mGFR decline (by C Cr-U ) in pre-dialysis patients with low ranges of kidney function is an important risk factor for mortality on dialysis, in contrast to eGFR decline.
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